Lista de obras -

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two: National Harbor, MD, USA. 9-13 November 2016

artículo científico publicado en 2016

Ad3-hTERT-E1A, a fully serotype 3 oncolytic adenovirus, in patients with chemotherapy refractory cancer

artículo científico publicado en 2012

CD40L coding oncolytic adenovirus allows long-term survival of humanized mice receiving dendritic cell therapy

scholarly article by Sadia Zafar et al published 2018 in OncoImmunology

Cancer-targeted oncolytic adenoviruses for modulation of the immune system

artículo científico publicado en 2017

Case-control estimation of the impact of oncolytic adenovirus on the survival of patients with refractory solid tumors

artículo científico publicado en 2014

Comparison of Familial Clustering of Anogenital and Skin Cancers Between In Situ and Invasive Types

scientific article published on 06 November 2019

Effect of Genetic Modifications on Physical and Functional Titers of Adenoviral Cancer Gene Therapy Constructs

article

Familial Associations in Testicular Cancer with Other Cancers

scientific article published on 18 July 2018

Familial Clustering, Second Primary Cancers and Causes of Death in Penile, Vulvar and Vaginal Cancers

articulo cientifico

Familial Risks Between Urolithiasis and Cancer

artículo científico publicado en 2018

Familial Urinary Bladder Cancer with Other Cancers

artículo científico publicado en 2018

Familial risks for gallstones in the population of Sweden

artículo científico publicado en 2017

Familial risks in and between stone diseases: sialolithiasis, urolithiasis and cholelithiasis in the population of Sweden.

artículo científico publicado en 2018

Familial risks in urolithiasis in the population of sweden

artículo científico publicado en 2017

Immunological data from cancer patients treated with Ad5/3-E2F-Δ24-GMCSF suggests utility for tumor immunotherapy ⬇️

artículo científico publicado en 2015

Impact noise of prostate biopsy devices

artículo científico publicado en 2020

Impact of family history of cancer on risk and mortality of second cancers in patients with prostate cancer

artículo científico publicado en 2018

Induction of interferon pathways mediates in vivo resistance to oncolytic adenovirus

artículo científico publicado en 2011

Intravenously usable fully serotype 3 oncolytic adenovirus coding for CD40L as an enabler of dendritic cell therapy

artículo científico publicado en 2016

Oncograms Visualize Factors Influencing Long-Term Survival of Cancer Patients Treated with Adenoviral Oncolytic Immunotherapy.

artículo científico publicado en 2018

Oncolytic adenovirus type 3 coding for CD40L facilitates dendritic cell therapy of prostate cancer in humanized mice and patient samples

artículo científico publicado en 2020

Oncolytic adenovirus with temozolomide induces autophagy and antitumor immune responses in cancer patients

artículo científico publicado en 2013

Oncolytic viruses for cancer immunotherapy

scientific article published on 29 June 2020

Predictive and Prognostic Clinical Variables in Cancer Patients Treated With Adenoviral Oncolytic Immunotherapy

artículo científico publicado en 2016

Prostate cancer survivors: Risk and mortality in second primary cancers

artículo científico publicado en 2018

RE: Familial Cancer Clustering of Urothelial Cancer: A Population-Based Case-Control Study.

artículo científico publicado en 2018

Second cancers and causes of death in patients with testicular cancer in Sweden

artículo científico publicado en 2019

Serotype chimeric oncolytic adenovirus coding for GM-CSF for treatment of sarcoma in rodents and humans

artículo científico publicado en 2014

Serum HMGB1 is a predictive and prognostic biomarker for oncolytic immunotherapy

artículo científico publicado en 2015

Surveillance Bias in Cancer Risk After Unrelated Medical Conditions: Example Urolithiasis

artículo científico

The Incidence of Senile Cataract and Glaucoma is Increased in Patients with Plasma Cell Dyscrasias: Etiologic Implications

artículo científico publicado en 2016

Treatment of melanoma with a serotype 5/3 chimeric oncolytic adenovirus coding for GM-CSF: Results in vitro, in rodents and in humans

artículo científico publicado en 2015

Tumor microenvironment remodeling by an engineered oncolytic adenovirus results in improved outcome from PD-L1 inhibition

artículo científico publicado en 2020

Lista de obras de

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two: National Harbor, MD, USA. 9-13 November 2016

Ad3-hTERT-E1A, a fully serotype 3 oncolytic adenovirus, in patients with chemotherapy refractory cancer

CD40L coding oncolytic adenovirus allows long-term survival of humanized mice receiving dendritic cell therapy

Cancer-targeted oncolytic adenoviruses for modulation of the immune system

Case-control estimation of the impact of oncolytic adenovirus on the survival of patients with refractory solid tumors

Comparison of Familial Clustering of Anogenital and Skin Cancers Between In Situ and Invasive Types

Effect of Genetic Modifications on Physical and Functional Titers of Adenoviral Cancer Gene Therapy Constructs

Familial Associations in Testicular Cancer with Other Cancers

Familial Clustering, Second Primary Cancers and Causes of Death in Penile, Vulvar and Vaginal Cancers

Familial Risks Between Urolithiasis and Cancer

Familial Urinary Bladder Cancer with Other Cancers

Familial risks for gallstones in the population of Sweden

Familial risks in and between stone diseases: sialolithiasis, urolithiasis and cholelithiasis in the population of Sweden.

Familial risks in urolithiasis in the population of sweden

Immunological data from cancer patients treated with Ad5/3-E2F-Δ24-GMCSF suggests utility for tumor immunotherapy ⬇️

Impact noise of prostate biopsy devices

Impact of family history of cancer on risk and mortality of second cancers in patients with prostate cancer

Induction of interferon pathways mediates in vivo resistance to oncolytic adenovirus

Intravenously usable fully serotype 3 oncolytic adenovirus coding for CD40L as an enabler of dendritic cell therapy

Oncograms Visualize Factors Influencing Long-Term Survival of Cancer Patients Treated with Adenoviral Oncolytic Immunotherapy.

Oncolytic adenovirus type 3 coding for CD40L facilitates dendritic cell therapy of prostate cancer in humanized mice and patient samples

Oncolytic adenovirus with temozolomide induces autophagy and antitumor immune responses in cancer patients

Oncolytic viruses for cancer immunotherapy

Predictive and Prognostic Clinical Variables in Cancer Patients Treated With Adenoviral Oncolytic Immunotherapy

Prostate cancer survivors: Risk and mortality in second primary cancers

RE: Familial Cancer Clustering of Urothelial Cancer: A Population-Based Case-Control Study.

Second cancers and causes of death in patients with testicular cancer in Sweden

Serotype chimeric oncolytic adenovirus coding for GM-CSF for treatment of sarcoma in rodents and humans

Serum HMGB1 is a predictive and prognostic biomarker for oncolytic immunotherapy

Surveillance Bias in Cancer Risk After Unrelated Medical Conditions: Example Urolithiasis

The Incidence of Senile Cataract and Glaucoma is Increased in Patients with Plasma Cell Dyscrasias: Etiologic Implications

Treatment of melanoma with a serotype 5/3 chimeric oncolytic adenovirus coding for GM-CSF: Results in vitro, in rodents and in humans

Tumor microenvironment remodeling by an engineered oncolytic adenovirus results in improved outcome from PD-L1 inhibition